242 related articles for article (PubMed ID: 31967907)
1. Targeted Alpha Therapy with Thorium-227.
Frantellizzi V; Cosma L; Brunotti G; Pani A; Spanu A; Nuvoli S; De Cristofaro F; Civitelli L; De Vincentis G
Cancer Biother Radiopharm; 2020 Aug; 35(6):437-445. PubMed ID: 31967907
[TBL] [Abstract][Full Text] [Related]
2. Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Hagemann UB; Wickstroem K; Hammer S; Bjerke RM; Zitzmann-Kolbe S; Ryan OB; Karlsson J; Scholz A; Hennekes H; Mumberg D; Cuthbertson AS
Cancer Biother Radiopharm; 2020 Sep; 35(7):497-510. PubMed ID: 32255671
[TBL] [Abstract][Full Text] [Related]
3. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Hagemann UB; Ellingsen C; Schuhmacher J; Kristian A; Mobergslien A; Cruciani V; Wickstroem K; Schatz CA; Kneip C; Golfier S; Smeets R; Uran S; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Mumberg D; Ziegelbauer K; Cuthbertson AS
Clin Cancer Res; 2019 Aug; 25(15):4723-4734. PubMed ID: 31064781
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
Hammer S; Hagemann UB; Zitzmann-Kolbe S; Larsen A; Ellingsen C; Geraudie S; Grant D; Indrevoll B; Smeets R; von Ahsen O; Kristian A; Lejeune P; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS; Mumberg D
Clin Cancer Res; 2020 Apr; 26(8):1985-1996. PubMed ID: 31831560
[TBL] [Abstract][Full Text] [Related]
5. In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia.
Hagemann UB; Wickstroem K; Wang E; Shea AO; Sponheim K; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS
Mol Cancer Ther; 2016 Oct; 15(10):2422-2431. PubMed ID: 27535972
[TBL] [Abstract][Full Text] [Related]
6. Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part I: purification of decayed thorium-227 on cation exchange columns.
Frenvik JO; Dyrstad K; Kristensen S; Ryan OB
Drug Dev Ind Pharm; 2017 Feb; 43(2):225-233. PubMed ID: 27628177
[TBL] [Abstract][Full Text] [Related]
7. Advances in targeted alpha therapy for prostate cancer.
De Vincentis G; Gerritsen W; Gschwend JE; Hacker M; Lewington V; O'Sullivan JM; Oya M; Pacilio M; Parker C; Shore N; Sartor O;
Ann Oncol; 2019 Nov; 30(11):1728-1739. PubMed ID: 31418764
[TBL] [Abstract][Full Text] [Related]
8. Synergistic Effect of a Mesothelin-Targeted
Wickstroem K; Hagemann UB; Cruciani V; Wengner AM; Kristian A; Ellingsen C; Siemeister G; Bjerke RM; Karlsson J; Ryan OB; Linden L; Mumberg D; Ziegelbauer K; Cuthbertson AS
J Nucl Med; 2019 Sep; 60(9):1293-1300. PubMed ID: 30850485
[TBL] [Abstract][Full Text] [Related]
9. Targeted alpha therapy: part I.
Elgqvist J
Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
[TBL] [Abstract][Full Text] [Related]
10. Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part II: purification of targeted thorium conjugates on cation exchange columns.
Frenvik JO; Dyrstad K; Kristensen S; Ryan OB
Drug Dev Ind Pharm; 2017 Sep; 43(9):1440-1449. PubMed ID: 28402142
[TBL] [Abstract][Full Text] [Related]
11. Targeted α-Therapy.
Brechbiel MW
Cancer Biother Radiopharm; 2020 Aug; 35(6):397. PubMed ID: 32503377
[No Abstract] [Full Text] [Related]
12. Targeted Alpha Therapy: Current Clinical Applications.
Guerra Liberal FDC; O'Sullivan JM; McMahon SJ; Prise KM
Cancer Biother Radiopharm; 2020 Aug; 35(6):404-417. PubMed ID: 32552031
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.
Wickstroem K; Hagemann UB; Kristian A; Ellingsen C; Sommer A; Ellinger-Ziegelbauer H; Wirnitzer U; Hagelin EM; Larsen A; Smeets R; Bjerke RM; Karlsson J; Ryan OB; Wengner AM; Linden L; Mumberg D; Cuthbertson AS
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):410-422. PubMed ID: 31255687
[TBL] [Abstract][Full Text] [Related]
14. Preparation of
Westrøm S; Generalov R; Bønsdorff TB; Larsen RH
Nucl Med Biol; 2017 Aug; 51():1-9. PubMed ID: 28486098
[TBL] [Abstract][Full Text] [Related]
15. Development of Targeted Alpha Particle Therapy for Solid Tumors.
Tafreshi NK; Doligalski ML; Tichacek CJ; Pandya DN; Budzevich MM; El-Haddad G; Khushalani NI; Moros EG; McLaughlin ML; Wadas TJ; Morse DL
Molecules; 2019 Nov; 24(23):. PubMed ID: 31779154
[TBL] [Abstract][Full Text] [Related]
16. The potential radio-immunotherapeutic α-emitter
Collins SM; Keightley JD; Ivanov P; Arinc A; Fenwick AJ; Pearce AK
Appl Radiat Isot; 2019 Mar; 145():251-257. PubMed ID: 30686576
[TBL] [Abstract][Full Text] [Related]
17. Molecular targeted α-particle therapy for oncologic applications.
Wadas TJ; Pandya DN; Solingapuram Sai KK; Mintz A
AJR Am J Roentgenol; 2014 Aug; 203(2):253-60. PubMed ID: 25055256
[TBL] [Abstract][Full Text] [Related]
18. Targeted α-therapy using 227Th-APOMAB and cross-fire antitumour effects: preliminary in-vivo evaluation.
Staudacher AH; Bezak E; Borysenko A; Brown MP
Nucl Med Commun; 2014 Dec; 35(12):1284-90. PubMed ID: 25192189
[TBL] [Abstract][Full Text] [Related]
19. Radionuclide antibody-conjugates, a targeted therapy towards cancer.
Kitson SL; Cuccurullo V; Moody TS; Mansi L
Curr Radiopharm; 2013 Jun; 6(2):57-71. PubMed ID: 23808764
[TBL] [Abstract][Full Text] [Related]
20. Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.
; Parker C; Lewington V; Shore N; Kratochwil C; Levy M; Lindén O; Noordzij W; Park J; Saad F
JAMA Oncol; 2018 Dec; 4(12):1765-1772. PubMed ID: 30326033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
